Related Experiment Videos
Prostaglandin inhibitors in preterm labour.
Jenifer A Z Loudon1, Kate M Groom, Philip R Bennett
1Imperial College Parturition Group, Institute of Reproductive and Developmental Biology, Imperial College School of Medicine, Hammersmith Hospital Site, London, UK. j.loudon@imperial.ac.uk
Best Practice & Research. Clinical Obstetrics & Gynaecology
|September 16, 2003
Summary
Anti-inflammatory drugs can prevent preterm labor, but indomethacin has fetal side effects. COX-2 selective drugs are being investigated to reduce these risks, but their safety is still under evaluation.
Area of Science:
- Obstetrics and Gynecology
- Neonatal Medicine
- Pharmacology
Background:
- Preterm birth is a leading cause of neonatal morbidity and mortality.
- Labor involves prostaglandin and cytokine production, suggesting a role for anti-inflammatory drugs.
- Indomethacin is an effective tocolytic but carries fetal risks like ductal constriction and renal impairment.
Purpose of the Study:
- To evaluate the potential of cyclo-oxygenase-2 (COX-2) selective drugs as tocolytics for preterm labor.
- To determine if COX-2 selective drugs can prevent preterm delivery while minimizing fetal side-effects associated with non-selective NSAIDs.
- To assess the safety and efficacy of COX-2 selective agents in managing preterm labor.
Main Methods:
- Review of current literature on tocolytic agents and their mechanisms of action.
- Analysis of studies investigating indomethacin and its known fetal side effects.
- Examination of clinical experiences and reported outcomes with COX-2 selective drugs (sulindac, nimesulide) in preterm labor.
Main Results:
- Indomethacin is the only tocolytic proven to delay delivery beyond 37 weeks and reduce low birth weight.
- Fetal side effects of indomethacin include ductal constriction and impaired renal function.
- Limited experience with COX-2 selective drugs like sulindac and nimesulide has shown potential for ductal constriction and oligohydramnios, with unclear mechanisms.
Conclusions:
- While indomethacin is effective, its fetal side effects necessitate alternative treatments.
- COX-2 selective drugs were hypothesized to offer targeted anti-inflammatory action, potentially reducing fetal risks.
- Current evidence on COX-2 selective drugs is insufficient to confirm their safety and efficacy, warranting their use only within randomized controlled trials.